Stopping Involuntary Movements
(Ivanhoe Newswire) — Results of the first, long-term clinical trial show the investigational drug safinamide may reduce dyskinesia (involuntary movements) in mid-to-late stage Parkinson’s disease.
“Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems,” study author Ravi Anand, M.D., a consultant with Newron Pharmaceuticals in Bresso, Italy, was quoted as saying. “These results are an important step forward in understanding how safinamide impacts patients with severe Parkinson’s disease. Symptoms of Parkinson’s disease such as motor fluctuations and dyskinesia can greatly affect a person’s daily living and quality of life.”
For the two-year study, 669 patients with mid-to-late stage Parkinson’s disease who were already taking levodopa and other dopaminergic treatments were given 50 or 100 milligrams of safinamide per day or a placebo pill. Scientists tested participants’ movement ability using the United Parkinson’s Disease Rating Scale that measures activities such as tremor, speech, behavior, mood and daily activities including swallowing, dressing and walking. A specific tool measuring severity of dyskinesia (DRS) was used in addition as a primary efficacy endpoint.
At the start of the study, patients who took the 50-milligram dose of safinamide had an average score of 3.9 compared to a score of 3.4 for those taking a placebo pill. Patients who took the 100-milligram dose had an average score of 3.7.
After two years, researchers discovered in a post-hoc analysis that safinamide at 100 milligrams a day on top of taking levodopa reduced dyskinesia, or movement problems, by 24-percent in the one-third of participants who had scored a four or higher on the dyskinesia rating scale at the beginning of the study compared to those taking a placebo. There were no significant differences for people who took the 50-milligram dose.
There were no significant differences in the primary efficacy measure (movement control, i.e., dyskinesia) scores in the overall population. Side effects were comparable among the three treatment groups.
SOURCE: 63rd Annual Meeting of the American Academy of Neurology, held April 9, 2011 in Honolulu, Hawaii